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Abstract  
Background: Whole-gland salvage Iodine-125-brachytherapy is a potentially curative treatment strategy 
for localised prostate cancer (PCa) recurrences after radiotherapy. Prognostic factors influencing PCa-
specific and overall survival (PCaSS & OS) are not known. The objective of this study was to develop a 
multivariable, internally validated prognostic model for survival after whole-gland salvage I-125-
brachytherapy.    
Materials and methods: Whole-gland salvage I-125-brachytherapy patients treated in the Netherlands 
from 1993-2010 were included. Eligible patients had a transrectal ultrasound-guided biopsy-confirmed 
localised recurrence after biochemical failure (clinical judgement, ASTRO or Phoenix-definition). 
Recurrences were assessed clinically and with CT and/or MRI. Metastases were excluded using CT/MRI 
and technetium-99m scintigraphy. Multivariable Cox-regression was used to assess the predictive value 
of clinical characteristics in relation to PCa-specific and overall mortality. PCa-specific mortality was 
defined as patients dying with distant metastases present. Missing data was handled using multiple 
imputation (20 imputed sets). Internal validation was performed and the C-statistic calculated. 
Calibration plots were created to visually assess the goodness-of-fit of the final model. Optimism-
corrected survival proportions were calculated. All analyses were performed according to the TRIPOD 
statement. 
Results: Median total follow-up was 78 months (range 5-139). A total of 62 patients were treated, of 
which 28 (45%) died from PCa after mean (±SD) 82 (±36) months. Overall, 36 patients (58%) patients 
died after mean 84 (±40) months. PSA doubling time (PSADT) remained a predictive factor for both types 
of mortality (PCa-specific and overall): corrected hazard ratio’s (HR’s) 0.92 (95%-CI: 0.86-0.98, p=0.02) 
and 0.94 (95%-CI: 0.90-0.99, p=0.01), respectively (C-statistics 0.71 and 0.69, respectively). Calibration 
was accurate up to 96 months follow-up. Over 80% of patients can survive 8 years if PSADT>24 months 
(PCaSS) and >33 months (OS). Only approximately 50% survival is achieved with a PSADT of 12 months. 
Conclusion: A PSADT of respectively >24 months and >33 months can result in >80% probability of PCa- 
specific and overall survival 8 years after whole-gland salvage I-125-brachytherapy. Survival should be 
weighed against toxicity from a salvage procedure. Larger series and external validation are necessary. 
 
 
 
 
 
 
 
Introduction  
Brachytherapy and external beam radiotherapy (EBRT) can achieve high tumour control in patients with 
primary prostate cancer1,2. EBRT dose escalation has led to further improvement of these results1,3. 
However, depending on tumour characteristics, PSA-parameters and use of androgen deprivation 
therapy (ADT), biochemical recurrences can still occur in 30-50% of patients after 5-10-years1,3. Over 
80% of patients can harbour a prostate-only recurrence4. Local salvage therapy is a potentially curative 
treatment for these prostate-confined recurrences. Whole-gland salvage can be performed using 
different techniques and is able to achieve long term biochemical control and survival and thereby 
postpone the use of androgen deprivation therapy (ADT) in carefully selected patient groups5-9.  
Risk factors for failure and mortality for salvage brachytherapy have not been comprehensively defined, 
because of small series with often limited events5,9,10. A few series have defined pre-salvage PSA, PSA-
doubling time (PSADT) and time-to-relapse after primary therapy as possible predictors of biochemical 
failure after salvage brachytherapy11-13. Although biochemical failure often precedes the development of 
distant metastases and death1, no predictive factors for survival have as of yet been identified. In this 
report, we therefore aimed to develop a prognostic model for PCa-specific survival (PCaSS) and overall 
survival (OS) after whole-gland salvage 125-brachytherapy, based on the largest salvage I-125-
brachytherapy cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
Patient selection, data collection and outcome assessment 
 
The institutional review board of the University Medical Center Utrecht (UMCU) permitted the analysis 
of the data. In total, 62 patients were treated with whole-gland salvage I-125-brachytherapy from 
November 1993 until April 2010 in both the University Medical Center, Utrecht (n=33) and the 
Radiotherapeutic institute RISO, Deventer, the Netherlands (n=29). Selection was based on objective 
assessment of a localised recurrence after biochemical failure (according to clinical judgement and the 
ASTRO or Phoenix definition after 1996 and 2005, respectively). Localised disease was transrectal 
ultrasound-guided biopsy-confirmed, with absence of lymph node or distant metastases based on pelvic 
CT and/or MRI (n=22) and technetium-99m scintigraphy (bone-scan). Transrectal ultrasound (in all 
patients) or MRI (in 22 patients) was used to exclude capsular extension. PSA, PSA-kinetics and other 
prognostic factors before primary therapy and salvage were not used for selection and were judged by 
the treating radiation oncologist. ADT was discontinued at salvage. 
Survival data was obtained by the primary researcher (MP) from patient charts. Survival was subdivided 
in prostate cancer specific survival (PCaSS) and overall survival (OS) after salvage brachytherapy. PCaSS 
was separately evaluated using the records by two independent radiation oncologists (JVZ, CH). For 
death due to prostate cancer, it was necessary to have distant metastases.  
Toxicity 
Late (>6 months post-implantation) severe (≥ grade 3) gastrointestinal (GI) and genitourinary (GU) 
toxicity was evaluated with the common terminology criteria for adverse events (CTCAE 4.03). 
Implantation details 
The prescription for the prostatic V100 (volume of the prostate receiving 100% dose [=145 Gy]) was 
≥95%. The D90 (minimal dose received by 90% of the prostate) was ≥145 Gy. In the UMCU images were 
imported in the Sonographic Planning of Oncology Treatment planning software (SPOT, Nucletron BV, 
Veenendaal, the Netherlands). The planning system in the RISO consisted of subsequent versions of 
VariseedTM (Varian Medical Systems, Palo Alto, CA). Loose and stranded seeds were both used in this 
cohort.  
Analysed predictive factors  
 
Factors before primary radiotherapy consisted of primary treatment (Iodine-125 brachytherapy or 
EBRT/IMRT), dose (>64.4 Gy or ≤64.4Gy), initial PSA (iPSA), T stage (1, 2 or 3) and initial Gleason grade 
(2-6, 7, or 8-10). Sub-classification of T-stage was frequently missing, so only the overall T-stage was 
used. Factors before salvage brachytherapy were PSA-nadir (i.e. the lowest PSA-value) after primary 
treatment, (biochemical) disease free survival interval (DFSI) after primary radiotherapy, age, PSA, 
PSADT, PSA-density (=PSA-value divided by the prostatic volume as assessed on ultrasound), PSA-
velocity and ADT-use. Gleason score pre-salvage was not analysed because of the chance of 
misclassification due to radiation effects (and therefore frequently missing scores)14. PSA kinetics (PSA-
velocity and PSADT) were calculated using the Memorial Sloan Kettering Cancer Center calculator15.  
PSA-nadir after salvage was separately analysed, because of its redundancy in patient selection. No 
interactions between variables were considered. 
Statistical analysis 
Normally distributed variables are presented as mean (±SD), skewed distributed variables as medians 
with ranges, and categorical data as frequencies with percentages. Kaplan-Meier survival analyses for 
PCaSS and OS were performed for categories of possible predictor variables. Categories of predictors 
were based on common prognostic categories from the literature (e.g. PSA ≤10 and >10 ng/ml and 
PSADT≤ 10 months and >10 months16). Receiver operating characteristic (ROC)-analysis was performed 
for PSA-density and PSA-velocity to identify cutoff values with maximal sensitivity and specificity, since 
groups were unequal when categories based on the literature were adopted. Differences were tested 
with the log-rank test.  
Missing data was considered at random. Multiple imputation (MI) with the iterative Markov Chain 
Monte Carlo method was performed (20 iterations)17,18. The MI-procedure was performed with all 
predictors listed above in the imputation process, including the outcome (PCaSS and OS)18,19.  
 
Model building 
 
Univariable and multivariable Cox-proportional hazards regression was performed. Before Cox-
regression, correlation coefficients between PSA, PSA kinetic factors and other predictors were 
calculated. Pearson’s correlation coefficient was used in case of linear relations and Spearman’s rank 
correlation in case of a non-linear correlation. Factors were excluded from multivariable analysis when 
collinearity was present (i.e. correlation coefficient ≥0.75). When (multi)collinearity was present, the 
factor measurable with the least practical effort was given priority to aid clinical application. From 
univariable analysis, factors were selected for multivariable analysis if p<0.10 based on the Wald-test. 
Stepwise backward elimination was used for the multivariable analysis and the models were compared 
at each step with the likelihood ratio test statistic. Proportional hazards was visually evaluated with log-
log curves for categorical predictors and Schoenfeld residuals for continuous variables. Survival 
proportions were calculated with (S(t)=S(0)exp(βpredictor1*predictor1 + βpredictor2*predictor2 etc.)). The β’s are the natural 
logarithm of the hazard ratio’s from multivariable analysis. S(0) is the baseline survival proportion at a 
specified follow-up point with determinants from multivariable analysis equaling 0. No correction for 
multiple testing was performed since parameters were often highly correlated with one another, 
thereby possibly inducing type II errors when conservatively adjusting the α-level.  
 
Internal validation and calibration 
 
Harrell’s C-statistic (concordance index) was used as a discrimination measure, comparable to an area-
under-the-curve (AUC) value from logistic regression20. With 500 bootstrapping resamples for each of 
the 20 imputed datasets, the optimism of the model and shrinkage factor for the coefficients were 
calculated, after which the C-statistic and coefficients (and subsequently HR’s) could be adjusted. 
The predictive accuracy for PCaSS and OS was visualised with calibration plots at 5 and 8-years. No 
external validation could be performed. Kaplan-Meier survival analysis, MI and Cox-proportional hazards 
regression procedures were performed using IBM SPSS version 20 (statistical package for the social 
sciences Inc, Chicago, IL). R language environment (version 3.1.2) for statistical computing (available at 
http://www.r-project.org/21) was used for calibration and internal validation (survival and rms package). 
Statistical significance was set at p ≤0.05. All procedures and reporting were based on the transparent 
reporting of multivariable prediction models for individual prognosis or diagnosis (TRIPOD) statement22.    
 
Results 
Patient characteristics  
Primary radiotherapy consisted of 64.4 Gy in 23 fractions of 2.3 Gy in the majority of patients (n=26, 
45%). Most patients had favourable tumor characteristics before primary radiotherapy and salvage, 
although outliers were present (e.g. PSA before salvage was 92.6 ng/ml in one patient, with the second 
highest 25.5 ng/ml) (Table 1). Response to salvage was present in 51 (82%) of 62 patients. Median total 
follow-up was 78 months (range 5-139). In total, 36 patients (58%) patients died during follow-up. The 
mean time to death was 84 (±40) months. Twenty-eight (45%) patients died due to PCa after 82 (±36) 
months. Eight patients died unrelated to the PCa, six of whom did not experience biochemical failure.  
Toxicity 
Data to assess GI and GU toxicity was available for 60 and 61 patients, respectively. A total of 12 patients 
(20%) experienced radiation proctitis for which they were treated with argon plasma laser coagulation. 
Late ≥grade 3 GU toxicity was present in 18 patients (30%). Urethral strictures (n=10) and urinary 
retention (n=4) were most frequently observed. Finally, 5 patients (8%) were observed with a combined 
toxicity profile with both GI and GU toxicity: two patients had a grade 3 and one patient a grade 4 
rectovesical fistula. Lastly, two patients experienced a grade 3 rectourethral fistula.          
Kaplan-Meier survival analysis 
The 10-year estimated PCaSS was 43%, with median survival of 108 months (95% CI: 91-125). After 10-
years, OS was 34%, with a median survival of 104 months (95% CI: 94-115).  
Patients with a pre-salvage PSA ≤10 ng/ml had 10-year PCaSS of 65% versus 15% for patients with 
PSA>10 ng/ml (log rank: p<0.0001). OS also differed, with 10-year OS being 53% versus 12%, respectively 
(p<0.0001). Patients with a PSADT >10 months compared to ≤10 months had a 10-year PCaSS of 71% 
versus 22%, (p=0.002), and an OS of 47% versus 21% (p=0.03), respectively. Other prognostic variables 
significantly associated with decreased PCaSS and OS were DFSI<36 months, PSA-density>0.25 ng/ml/cc, 
PSA-velocity>3ng/ml/year and nadir after salvage>1.0 ng/ml. Primary patient and tumor characteristics 
were not associated with survival after salvage. Primary Gleason 8-10 tumours were almost significantly 
related to survival compared to Gleason 2-6 and 7, but the group consisted of only 3 cases. Kaplan-
Meier results are depicted in Table 2 and supplementary figures. 
Missing data 
No outcome data was missing. Predictor variables not standardised in follow-up had the most missing 
values (PSA-velocity and DFSI, both 11 [17.7%]). There was significant overlap in missing data, with 
approximately 80% of cases having no missing values. Because of no intrinsic relation with the missing 
values or the outcomes, data was considered missing at random. Table 1 lists further information on 
missing data.  
Correlation 
Pre-salvage PSA and PSA-density showed the highest correlation (Pearson correlation coefficient 0.95, 
p<10-29). Pre-salvage PSA and PSA-velocity were also highly correlated (Spearman’s rank correlation 0.8, 
p<10-11). All other significant correlations were <0.75. The largest of these correlation was between pre-
salvage PSA and DFSI (Spearman: -0.65, p<10-6), DFSI and PSADT (Pearson: 0.58, p<0.0001) and between 
PSA and nadir-after salvage (Spearman: 0.51, p<0.001). Due to these correlations, PSA-density and PSA-
velocity were excluded from the multivariable Cox-regression analysis. PSA was kept in, because it 
consists of only a single measurement.  
 
Modelling results, internal validation and calibration 
Univariable analysis showed PSA, PSADT, PSA-velocity and PSA-nadir after salvage as significant 
predictors for PCaSS and OS. For PCaSS, PSA-density and DFSI were almost significant (p=0.06 and 
p=0.054). For OS, significance of DFSI disappeared (p=0.13). Univariable, ADT use was almost significant 
for OS (p=0.08). After multivariable analysis for PCaSS (variables included: DFSI, PSA and PSADT), only 
PSADT remained as a significant predictor: corrected hazard ratio (HR) 0.92 (95%-CI: 0.86-0.98, p=0.02), 
indicating an approximate 8% decrease in hazard for PCaSS for each month increase in PSADT. PSADT 
remained a significant predictor for OS after multivariable analysis (variables included: ADT, PSA and 
PSADT): corrected HR 0.94 (95%-CI: 0.90-0.99, p=0.01), respectively (Table 3). There were no violations 
of the proportional hazards assumption. The apparent C-statistic was 0.73 for PCaSS 0.71 for OS and 
adjusted 0.71 and 0.69, respectively. Shrinkage factors were 0.77 for PCaSS and 0.71 for OS. Calibration 
plots after 5 and 8 years are depicted in Figure 1. Observed survival frequencies are concordant with 
predicted probabilities from the final models up to 8 years.  
Survival proportions 
Baseline cumulative survival proportions (S(0)) for PCaSS and OS at 8 years were 0.215 and 0.219, 
respectively. In patients with a pre-salvage PSADT>24 months, whole-gland salvage I-125-brachytherapy 
results in a >80% chance of PCaSS up to 8 years. For OS, a PSADT >33 months results in this survival 
percentage (Figure 2 and supplementary table 4). With a PSADT of 12 months or lower, survival dropped 
to approximately ≤50%.  
Discussion 
In summary, our study has shown a relation with several pre-salvage characteristics and both prostate 
cancer specific and overall survival after whole-gland salvage I-125-brachytherapy for localised prostate 
cancer recurrences after primary radiotherapy. After multivariable Cox analysis, only PSADT remained a 
predictor of both PCaSS and OS: corrected hazard ratio (HR) 0.92 (95%-CI: 0.86-0.98, p=0.02) and 0.94 
(95%-CI: 0.90-0.99, p=0.01), respectively. This implies a decrease in hazard for mortality of 
approximately 8% and 6% with every month increase in PSADT, respectively.  
To our knowledge these 62 patients constitute the largest whole-gland salvage I-125-brachytherapy 
series, with sufficient events for prognostic modelling. We have used the recent TRIPOD statement 
regarding the conduct and reporting of prognostic research22, to ensure transparent reporting of 
handling variables, missing data, model building, validation and calibration. We trust this might facilitate 
comparison with future groups reporting on salvage I-125-brachytherapy outcomes. For now, with the 
optimism-corrected hazard ratio’s for PSADT and baseline survival proportion, exact survival 
percentages can be calculated in clinical practice for individual patients.  
Nonetheless, our study has some limitations. At 8 years, calibration was decent for both PCaSS and OS, 
although with a relatively large spread as is visible in the wide confidence intervals of the observed 
(Kaplan-Meier) survival estimates. The same is applicable to the predicted survival probabilities. Larger 
groups and possibly other predictors are necessary to add precision to the current estimates. 
It is possible that factors not taken into account for this analysis, such as pre-salvage Gleason grade8 and 
morphological findings on MRI (and/or functional sequences), might have additional predictive ability 
for progression and survival. These were not available in the current patient cohort. Furthermore, a type 
I error in one/some of the assessed parameters is a possibility due to multiple testing. However, 
parameters were often (highly) correlated with one another, thereby reducing the risk of a type I error. 
Also, correcting the α-level conservatively with a Bonferroni, Šídák or Holm’s Sequential Bonferroni 
procedure would assume independence of the separate tests and therefore automatically increase the 
chance of a type II error (i.e. incorrect non-significant results). Furthermore, PSADT had a significant 
relation with both types of mortality, making a type I error less likely (even though both types of 
mortality show overlap). Lastly, an explorative approach was adopted for this set of clinical variables, 
since this database is the largest nowadays for whole-gland salvage I-125-brachytherapy. This could 
provide valuable insight into which variables are important for future research into the topic. They do 
have to be verified in other series, however.  
Interestingly, factors before primary radiotherapy do not show an effect on survival. Selection of salvage 
patients is often performed based on these characteristics16,23. These findings could be an indication of 
their relative insignificance for patient selection. Contrary to this hypothesis, Gleason 8-10 before 
primary radiotherapy consisted of only 3 patients and showed a tendency in the Kaplan-Meier analysis 
to low survival. The prognostic relevance of this factor could have been underestimated in our analysis. 
Quantification can be provided when larger numbers are assessable.  
Lastly, without external validation this model cannot provide clinically robust estimates of predicted 
survival. External validation could decrease the predictive accuracy of PSADT as found in this population, 
since the current cohort consisted of a relatively dated and high risk population. This uncertainty needs 
to be taken into account when selecting whole-gland salvage I-125-brachytherapy patients based on 
their PSADT. However, as this is the only predictive factor from extensive multivariable analysis in 
predicting survival after whole-gland salvage prostate I-125-brachytherapy so far, it could provide 
additional guidance in the selection of patients in clinical practice or to intensify post-salvage follow-up 
in patients deemed at high risk for treatment failure and mortality. Patients with a PSADT <20 months 
require at least additional follow-up after salvage to assess disease progression or salvage should be 
offered earlier or perhaps not at all. Furthermore, the benefits of treatment regarding cancer 
control/survival need to be weighed against the exacerbated toxicity after whole-gland salvage I-125-
brachytherapy, as was observed in this and previous series5,6.  
 
Other series have provided risk factors for biochemical failure with small groups of whole-gland salvage 
LDR I-125/Pd-103 and HDR Ir-192-brachytherapy patients and even focal salvage approaches (directed 
locally at the recurrence)10-13,24-30. Only a few of the whole-gland salvage brachytherapy studies provide 
multivariable modelling, with often limited events, categorisation of predictor variables and insufficient 
description of handling missing data, leading to imprecise estimates11-13,26. However, there is no data on 
predictive factors for survival (PCaSS and OS). Predictive factors for survival in other salvage modalities 
(such as radical prostatectomy and cryosurgery) are more comprehensively defined, because of larger 
patient numbers and longer follow-up7,8. These factors (PSA pre-salvage, primary Gleason score, T-stage 
[both only univariable] and nadir after salvage, among other) are possibly important for salvage 
brachytherapy as well, but are not quantified in this setting with multivariable models.  
In addition, although biochemical failure often precedes the development of distant metastases and 
(PCa-specific) mortality1, it is unclear whether predictive factors associated with biochemical failure can 
be extrapolated to mortality in the case of salvage brachytherapy patients. Due to often more advanced 
age at salvage, it is questionable whether these factors will also predict survival in the same manner. 
Therefore, this analysis has provided the first identification of a pre-savage characteristic which can 
predict both types of survival in whole-gland salvage I-125-brachytherapy. The PSADT could be used to 
select patients or identify patient with a poor response to salvage and subsequently intensify follow-up 
or reject further salvage. The toxicity from such a procedure should be taken into account with this 
consideration as well.    
 
Conclusion 
PSADT is the only predictive factor for survival after whole-gland salvage I-125-brachytherapy. More 
than 80% survival can be achieved with PSADT>24 months (PCaSS) and >33 months (OS) up to 8 years 
after salvage. Only approximately 50% survival is achieved with a PSADT of 12 months and therefore, 
survival should be weighed against potential toxicity from a salvage procedure. Larger series, other 
predictive factors and external validation are warranted.  
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